1. Jones CA,McQuillan GM,Kusek JW (1998). Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases, 32(6), 992-999.
2. National Kidney Foundation (NKF),Kidney Disease Outcome Quality Initiative (K/DOQI),Advisory Board (2002). K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dise, 39(2 Suppl 2), S-249.
3. Fang Y,Ginsberg C,Sugatani T (2014). Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int, 85, 142.
4. Pereira RC,Juppner H,Azucena-Serrano CE (2009). Pttren of FGF-23, DMPI, and MEPE expression in patients with chronic kidney disease. Bone, 45, 1161.
5. Sabbagh Y,Graciolli FG,O’Brien S (2012). Repression of osteocyte Wnt/B-catenin signaling is as early event in the progression of renal osteodystrophy. J Bone Miner Res, 27, 175.
6. Oliveira RB,Cancela AL,Graciolli FG (2010). Early control of PTH and FGF-23 in nonmorphosphatemic CKD patients a new target in CKD-MBD therapy?. Cli J AM SocNephrol, 5, 286.
7. T. Isakova,P. Wahl,G. Vargas (2011). Correction to "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease". Kidney International, 82(4), 498.
8. Gutierrez O,Isakova T,Rhee E (2005). Fibroblast growth factor-23 mitigate hyperphosphatemia but accentuate calcitriol deficiency in chronic kidney disease. J AM SocNephrol, 16, 2205.
9. Cunningham J,Locatelli F,Rodriguez M (2011). Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Cli J AM SocNephrol, 6, 913.
10. Levin A,Bakris GL,Molitch M (2007). Prevelance of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. KidenyInt, 71, 31.
11. Pitts TO,Piraino BH,Mitro R (1988). Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metabolism, 67(5), 876.
12. Martin KJ,Gonzalez EA (2007). Metabolic bone disease in chronic kidney disease. J AM Soc Nephrol, 18(3), 875.
13. Davis Kates,Donald Sherrard,Dennis Andress (1997). Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. American Journal of Kidney Diseases, 30(6), 809-813.
14. Hruska KA,Teitelbaum SL (1995). Renal osteodystrophy. N Engl J Med, 333, 166.
15. Fournier A,Moriniere P,Ben F (1992). Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney IntSuppl, 38, S50.
16. F. Liach (1995). Liach F, Secondary hyperparathyroidism in renal failure; The trade-off hypothesis revisited. American Journal of Kidney Diseases, 25(5), 663-679.
17. J. Silver,R. Levi (2005). Silver J, Levi R. Cellular and molecular mechanisms of secondary hyperparathyroidism. Clinical Nephrology, 63(02), 119-130.
18. Wetmore JB,Liu S,Krebill R (2010). Effects of cinacalcet and concurrent low dose vitamin D on FGF23 levels in ESRD. Clin J AM Nephrol, 5, 110.
19. Saito H,Maeda A,Ohtomo S (2005). Circulating FGF- 23 is regulated by 1 alpha, 25 dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem, 280, 2543.
20. Koenig KG,Lindberg JS,Zerwekh JE (1992). Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int, 41(1), 161.
21. Wilson L,Felsenfeld A,Drezner MK,Liach F (1985). Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. Kidney Int, 27(3), 565.
22. Gutierrez OM,Isakova T,Andress DL (2008). Prevalence and severity of disordered mineral metabolism in blacks with chronic kidney disease. Kidney Int, 73(8), 956.
23. Chen Hsu,Sanjeevkumar Patel,Eric Young,Raymond Vanholder (1994). Hsu CH, Patel SR, Young EW, Vanholder R. The biological action of calcitriol in renal failure. Kidney International, 46(3), 605-612.
24. Silver J,Naveh-Many T,Mayer H (1986). Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest, 78(5), 1296.
25. Hartmut Malluche,Hanna Mawad,Nicholas Koszewski (2002). Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney International, 62(2), 367-374.
26. P. Brumbaugh,M. Hughes,M. Haussler (1975). Brumbaugh PF, Hughes MR, Haussler MR. Cytoplasmic and nuclear binding components for 1- alpha 25-dihydroxyvitamin D3 in chick parathyroid glands. Proceedings of the National Academy of Sciences, 72(12), 4871-4875.
27. Denda M,Finch J,Brown AJ (1996). 1,25- dihydroxyvitamin D3 and 22-oxacacitriol revent the decrease in vitamin D receptor content in parathyroid glands of uremic rats. Kidney Int, 50(1), 34.
28. Slatopolsky E,Weerts C,Thielan J (1984). Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest, 74(6), 2136.
29. Fukuda N,Tanaka H,Tominaga Y (1993). Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest, 92(3), 1436.
30. Rodriguez M,Nemeth E,Martin D (2005). The calciumsensing receptor: a key in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol, 288, F253.
31. Li YC,Amling M,Pirro AE (1998). Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology, 139(10), 4391.
32. Panda DK,Miao D,Bolivar I (2004). Inactivation of the 25-hydroxyvitamin D 1-alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem, 279(16), 16754.
